• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

软骨肉瘤患者中通过Ki67和异柠檬酸脱氢酶1(IDH1)进行的免疫组织化学分析

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA.

作者信息

Ribeiro Marcelo Barbosa, Ibiapina Jerúsia Oliveira, Baptista André Mathias, Camargo Olavo Pires DE

机构信息

Universidade Federal do Piaui, Teresina, PI, Brazil.

Centro Universitario Unifacid, Teresina, PI, Brazil.

出版信息

Acta Ortop Bras. 2023 Jul 17;31(3):e267212. doi: 10.1590/1413-785220233103e267212. eCollection 2023.

DOI:10.1590/1413-785220233103e267212
PMID:37469494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10353868/
Abstract

OBJECTIVE

To perform an immunohistochemical evaluation using the IDH1 and Ki67 markers in patients who underwent treatment for chondrosarcoma in a reference service center in Brazil.

METHODS

Retrospective analytical observational study using medical records of patients diagnosed with chondrosarcoma. Besides the epidemiological and clinical profile, important variables for prognosis and correlation with immunohistochemical analysis results with Ki67 and IDH1 markers were evaluated.

RESULTS

Histopathological examinations by immunohistochemistry of 56 patients were analyzed, 52% of which were women, with the age group 20-60 years being more prevalent. Grade 1 and 2 histological subtypes corresponded to most chondrosarcomas. The femur, humerus, and tibia were the most frequent anatomical sites. Most tumors (59%) were larger than 8 cm. Ki67 expression was very low (< 10%) in 98% of patients. The analysis of IDH1 was positive in 43% of the cases. The correlation between IDH1 positivity and tumor size was statistically significant, but regarding survival, we observed no significance.

CONCLUSION

Immunohistochemical analysis using IDH1 and Ki67 markers in patients with conventional chondrosarcoma is not useful for prognostic guidance.

摘要

目的

在巴西一家参考服务中心,对接受软骨肉瘤治疗的患者使用异柠檬酸脱氢酶1(IDH1)和Ki67标记物进行免疫组织化学评估。

方法

采用回顾性分析观察性研究,使用诊断为软骨肉瘤患者的病历。除了流行病学和临床特征外,还评估了预后的重要变量以及与Ki67和IDH1标记物免疫组织化学分析结果的相关性。

结果

对56例患者的免疫组织化学组织病理学检查进行了分析,其中52%为女性,20至60岁年龄组更为常见。1级和2级组织学亚型对应大多数软骨肉瘤。股骨、肱骨和胫骨是最常见的解剖部位。大多数肿瘤(59%)大于8厘米。98%的患者Ki67表达非常低(<10%)。43%的病例IDH1分析呈阳性。IDH1阳性与肿瘤大小之间的相关性具有统计学意义,但在生存方面,我们未观察到显著性差异。

结论

在传统软骨肉瘤患者中使用IDH1和Ki67标记物进行免疫组织化学分析对预后指导无用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ac/10353868/4da306d1067b/1809-4406-aob-31-03-e267212-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ac/10353868/4da306d1067b/1809-4406-aob-31-03-e267212-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ac/10353868/4da306d1067b/1809-4406-aob-31-03-e267212-gf1.jpg

相似文献

1
IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA.软骨肉瘤患者中通过Ki67和异柠檬酸脱氢酶1(IDH1)进行的免疫组织化学分析
Acta Ortop Bras. 2023 Jul 17;31(3):e267212. doi: 10.1590/1413-785220233103e267212. eCollection 2023.
2
Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients.IDH1、ATRX、Ki67、GFAP的免疫组化表达与印度尼西亚胶质瘤患者的预后
Int J Gen Med. 2023 Feb 1;16:393-403. doi: 10.2147/IJGM.S397550. eCollection 2023.
3
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.软骨肉瘤中 IDH 突变的预后意义:一项个体患者数据荟萃分析。
Cancer Med. 2021 Jul;10(13):4415-4423. doi: 10.1002/cam4.4019. Epub 2021 Jun 3.
4
Genomic Profiling Identifies Association of Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.基因组分析鉴定出高级别软骨肉瘤中突变与更长的无复发生存和无转移生存相关。
Clin Cancer Res. 2020 Jan 15;26(2):419-427. doi: 10.1158/1078-0432.CCR-18-4212. Epub 2019 Oct 15.
5
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.异柠檬酸脱氢酶1/2(IDH1/2)突变在鉴别去分化软骨肉瘤与骨未分化多形性肉瘤中的诊断效用
Hum Pathol. 2017 Jul;65:239-246. doi: 10.1016/j.humpath.2017.05.015. Epub 2017 May 25.
6
Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.鉴别脉络丛状脑膜瘤与其组织学相似肿瘤:一项免疫组化评估
Am J Surg Pathol. 2009 May;33(5):669-81. doi: 10.1097/PAS.0b013e318194c566.
7
Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones?针吸活检在骨盆和长骨中央型软骨肉瘤术前分级中临床有用吗?
Clin Orthop Relat Res. 2017 Mar;475(3):808-814. doi: 10.1007/s11999-016-4738-y.
8
Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas.
Int J Cancer. 1996 Apr 22;69(2):86-91. doi: 10.1002/(SICI)1097-0215(19960422)69:2<86::AID-IJC3>3.0.CO;2-R.
9
Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.靶向下一代测序鉴定去分化软骨肉瘤中的分子和遗传事件。
Arch Pathol Lab Med. 2021 Aug 1;145(8):1009-1017. doi: 10.5858/arpa.2020-0379-OA.
10
Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.胃肠道间质瘤的预后血管生成标志物(内皮糖蛋白、血管内皮生长因子、CD31)和肿瘤细胞增殖(Ki67)
World J Gastroenterol. 2015 Jun 14;21(22):6924-30. doi: 10.3748/wjg.v21.i22.6924.

引用本文的文献

1
Auricular epithelioid hemangioendothelioma: Two cases first diagnosed as auricular pseudocyst.耳廓上皮样血管内皮瘤:两例最初被诊断为耳廓假性囊肿。
Oncol Lett. 2024 Oct 21;29(1):17. doi: 10.3892/ol.2024.14763. eCollection 2025 Jan.

本文引用的文献

1
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.软骨肉瘤中 IDH 突变的预后意义:一项个体患者数据荟萃分析。
Cancer Med. 2021 Jul;10(13):4415-4423. doi: 10.1002/cam4.4019. Epub 2021 Jun 3.
2
The 2020 WHO Classification of Tumors of Bone: An Updated Review.2020 年世卫组织骨肿瘤分类:更新综述。
Adv Anat Pathol. 2021 May 1;28(3):119-138. doi: 10.1097/PAP.0000000000000293.
3
Genomic Profiling Identifies Association of Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
基因组分析鉴定出高级别软骨肉瘤中突变与更长的无复发生存和无转移生存相关。
Clin Cancer Res. 2020 Jan 15;26(2):419-427. doi: 10.1158/1078-0432.CCR-18-4212. Epub 2019 Oct 15.
4
Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis.软骨肉瘤亚型的生存和预后:SEER 数据库分析。
J Orthop Res. 2020 Feb;38(2):311-319. doi: 10.1002/jor.24463. Epub 2019 Sep 22.
5
Prognostic factors for patients with chondrosarcoma: A survival analysis based on the Surveillance, Epidemiology, and End Results (SEER) database (1973-2012).软骨肉瘤患者的预后因素:基于监测、流行病学和最终结果(SEER)数据库(1973 - 2012年)的生存分析
J Bone Oncol. 2018 Sep 18;13:55-61. doi: 10.1016/j.jbo.2018.09.003. eCollection 2018 Nov.
6
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma.异柠檬酸脱氢酶1/2(IDH1/2)突变预示着软骨肉瘤患者生存期较短。
J Cancer. 2018 Feb 28;9(6):998-1005. doi: 10.7150/jca.22915. eCollection 2018.
7
Corrigendum to "Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone" [Hum Pathol 2017;65:239-46].
Hum Pathol. 2017 Nov;69:143. doi: 10.1016/j.humpath.2017.10.001. Epub 2017 Nov 13.
8
Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.整合形态学与遗传学用于软骨肿瘤的诊断
Surg Pathol Clin. 2017 Sep;10(3):537-552. doi: 10.1016/j.path.2017.04.005.
9
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.第八版 AJCC 癌症分期手册:继续从基于人群的方法向更“个体化”的癌症分期方法构建桥梁。
CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17.
10
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.IDH1 和 IDH2 突变在中央性软骨肉瘤、中央性和骨膜性软骨瘤中较为常见,但在其他间叶肿瘤中不常见。
J Pathol. 2011 Jul;224(3):334-43. doi: 10.1002/path.2913. Epub 2011 May 19.